NCT07121829 2025-08-14
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 1 Terminated
Clinical Trials
3 trialsNCT02723006 2024-03-05
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Takeda
Phase 1 Terminated
NCT01425008 2020-08-10
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
Takeda
Phase 1 Completed